In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Tomato perfume reflects curiosity around hyper-specific, ingredient-led scents that invite consumers to reimagine familiar smells in a new context
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al
Naively, I transmitted the sales pitch to many of my Medicare patients
Some suggest splitting doses, others insist on single morning administration
Your doctor will help determine the most appropriate response to any side effects